Abstract: Astroglial cells secrete a variety of factors that contribute to the regulation of neurite initiation and continued outgrowth, among them proteases and protease inhibitors. An alteration in the balance between these proteins has been implicated in Alzheimer's disease, resulting in an accumulation of thrombin:protease nexin 1 (PN1) complexes in the brains of these patients. This report aims at providing a biochemical explanation for this phenomenon. We show that human astrocytoma cells bind and internalize thrombin and thrombin:PN1 complexes efficiently by a PN1-dependent mechanism. Binding was potently inhibited by soluble heparin and did not occur with the mutant PN1 (K7E) deficient in heparin binding. Receptor-associated protein, an antagonist of the low-density lipoprotein receptor-related protein (LRP), inhibited internalization of thrombin by the astrocytoma cells, but did not affect cell-surface binding. The results are consistent with a mechanism by which astrocytoma cells clear thrombin in a sequential manner: thrombin is first complexed with PN1, then bound to cell-surface heparins, and finally internalized by LRP. This mechanism provides a link between the neuronal growth regulators thrombin and PN1 and proteins genetically associated with Alzheimer's disease, such as LRP. Key Words: Thrombin-Protease nexin 1-Receptor-associated protein-Low-density lipoprotein receptor-related protein-Astrocytes-Alzheimer's disease. J. Neurochem. 72, 980 -987 (1999).
Neuritogenesis is heavily influenced by the surrounding glial environment. Among the many glial-derived factors that promote neurite formation are the protease nexins, which bind and suppress neuronal surface proteases and thereby mediate initial stages of neurite outgrowth. Protease nexin 1 (PN1), also known as glialderived nexin, is a 43-kDa serine protease inhibitor (SERPIN) that has been shown to promote neurite outgrowth in vitro from several different neuronal cell types (Monard et al., 1983; Sommer et al., 1987) and is secreted from glial cells (Festoff et al., 1991) . PN1 has been shown to be a bona fide neurotrophic factor, promoting the survival of spinal motor neurons and rescuing them from axotomy-induced cell death (Houenou et al., 1995) . The neurotrophic activity of PN1 is linked directly to its function as a thrombin inhibitor (Baker et al., 1980 (Baker et al., , 1986 Sommer et al., 1987; Monard et al., 1992) .
In an in vitro model, the proteolytic activity of thrombin was shown to be required for synapse reduction (Liu et al., 1994) and local inhibition of thrombin delayed synapse loss (Zoubine et al., 1996) at the neuromuscular junction.
Several studies show that the balance between thrombin and PN1 is upset in various injury states (Monard et al., 1992; Cunningham et al., 1993; Smith-Swintosky et al., 1995; Pike et al., 1996) . Thrombin and thrombin:PN1 complexes are significant components of senile plaques (Akiyama et al., 1992) . In patients with Alzheimer's disease (AD), free PN1 is decreased significantly in several areas of the brain, and a buildup of thrombin:PN1 complexes associated with plaques is observed (Rosenblatt et al., 1989; Wagner et al., 1989; Vaughan et al., 1994; Choi et al., 1995) . Two mechanisms may be at play in creating the imbalance between thrombin and PN1 in disease. First, the reduced levels of PN1 could be due to sequestration of PN1 by excess thrombin that has penetrated the blood-brain barrier in AD brains. There is indeed evidence for disruption of the blood-brain barrier in AD (Kalaria and Grahovac, 1990) . Second, clearance of thrombin and thrombin:PN1 complexes from the ex-tracellular space may be defective. The present studies were designed to establish the mechanisms that regulate clearance of thrombin:PN1 complexes in human astrocytoma cells, because these cells may be responsible for such clearance in vivo. Two cell-surface proteins were likely candidates for thrombin clearance based on previous work. The first, thrombomodulin (TM), has been shown to cause constitutive internalization of thrombin in COS cells (Conway et al., 1997) and endothelial cells (Teasdale et al., 1994) . The second, the low-density lipoprotein receptor-related protein (LRP), has been shown to be responsible for clearance of thrombin:PN1 complexes in fibroblasts Knauer, 1986, 1987; Stone et al., 1994; Knauer et al., 1997a) . Both TM (Pindon et al., 1997) and LRP have been observed on astrocytes.
TM and LRP both resemble the low-density lipoprotein receptor, but the mechanism of thrombin internalization by each of these proteins is expected to be different. Epidermal growth factor (EGF) domains 4 -6 of TM bind to the fibrinogen binding site of thrombin with nanomolar affinity. A second, weaker interaction is possible between the chondroitin sulfate moiety of TM and the heparin-binding site on thrombin. Thus, at high thrombin concentrations, two molecules of thrombin can bind to one molecule of TM (Ye et al., 1993) . The LRP, in contrast, is a multiligand receptor responsible for clearing a variety of protease-protease inhibitor complexes, including the thrombin:PN1 complex (for a review, see Gliemann et al., 1994) . We present experiments to ascertain whether either or both of these two proteins are responsible for thrombin clearance by human astrocytes.
EXPERIMENTAL PROCEDURES

Materials
Tissue culture dishes and plasticware were purchased from Corning, and cell culture reagents were from either Irvine Scientific or GibcoBRL. 1,3,4,6-Tetrachloro-3␣,6␣-diphenylglycouril (Iodo-Gen) was from Pierce. Na 125 I was purchased from Amersham. All other common reagents were from Fisher Scientific or Sigma.
Cell culture
Human astrocytic cells were obtained from ATCC. We selected the CCF-STTG1 cell line, which originates in astrocytoma (grade IV) human tumors, because they most closely resemble normal astrocytes. We shall hereafter refer to these cells as astrocytes. Glial fibrillary acidic protein (GFAP), an astrocyte-specific marker, has been reported to be present in 70 -80% of these cells in culture (Barna et al., 1985) . Cells were grown in T-flasks in RPMI 1640 medium containing glutamine, 10% fetal bovine serum, penicillin, and streptomycin. Medium was changed every 2 days, and cultures typically became confluent after 4 -5 days and were subcultured by splitting 1:4. Cells from one T75 confluent flask were trypsinized, washed, and diluted to 14 ml with fresh medium before being transferred to 24-well plates. Cultures in 24-well plates were confluent after 1-2 days and were serum-starved for 2-4 h in binding medium (Dulbecco's modified Eagle's medium without serum, containing 1 mg/ml bovine serum albumin, and 20 mM HEPES buffer, pH 7.2) before use in experiments.
To check for GFAP expression, cells were grown on LabTek chamber slides (Nunc) for 4 -5 days and fixed with 4% paraformaldehyde for 15 min. at 25°C. The cells were rinsed in phosphate-buffered saline (PBS) once and then in 70% ethanol for 10 min at 25°C. After three rinses with PBS containing 0.25% Triton X-100 (5 min each), the nonspecific adsorption of antibodies was blocked with 10% goat serum and 3% bovine serum albumin in PBS for 30 min. The preparations were incubated overnight at 4°C with a polyclonal antiserum against GFAP (Dako, at 1:500 dilution). After three rinses with PBS (5 min each), the cells were incubated for 1 h in a biotinylated goat anti-rabbit antiserum coupled with fluorescein isothiocyanate. After washes in PBS, the preparations were allowed to air dry and then viewed and photographed on a Zeiss microscope with epifluorescence, coupled to a Kodak DCS digital camera. The images were captured directly from the microscope using Adobe Photoshop software.
Proteins
The TM fragment TMEGF(4-5-6) was prepared as previously described (White et al., 1995) . Human PN1, the heparinbinding deficient variant PN1(K7E), and the fusion protein of receptor-associated protein (RAP) with glutathione S-transferase (GST-RAP) were prepared as described previously (Herz et al., 1991; Knauer et al., 1997b) . Human thrombin was radioiodinated using Iodo-Gen as previously described (Howard and Knauer, 1986) . Specific activities ranged from 15,000 to 20,000 cpm/ng. Complexes of 125 I-thrombin with PN1 and PN1(K7E) were prepared in binding medium by incubation at 37°C for 40 min. The degree of complex formation was ascertained by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis in which 125 I-thrombin:PN1 complexes (80 kDa) and 125 I-thrombin alone (30 kDa) were separated and quantified by phosphorimaging (Knauer et al., 1997a,b) .
Internalization and degradation of thrombin:PN1 complexes
Internalized and degraded thrombin or thrombin:PN1 complexes were measured by determination of the amount of 125 I present in the soluble portion of the culture media after trichloroacetic acid (TCA) precipitation (Howard and Knauer, 1986) . At the start of the experiment, cells were washed twice with bicarbonate-free binding medium.
125 I-Thrombin:PN1 complexes (450 l in binding medium) were incubated with duplicate 24-well confluent cultures of astrocytes. At the indicated times, 100-l aliquots of the media were removed and added to 1 ml of ice-cold TCA. Bovine serum albumin (50 l of a 3% solution) was added as a carrier protein, and the precipitation was carried out overnight. The supernatant was collected after centrifugation at 5,000 g for 30 min at 4°C, and the radioactivity in aliquots was quantified by ␥ counting. Complex degradation was measured by the appearance of TCA-soluble radioactivity (primarily 125 I-Tyr). Background counts from complexes not incubated with cells were subtracted from each time point. For experiments in which inhibition of internalization and degradation by GST-RAP or heparin was ascertained, the GST-RAP or heparin was added to the complexes after complex formation and before incubation of the complexes with the cells.
Binding of thrombin:PN1 complexes to cells
Duplicate confluent astrocyte cultures in 24-well plates were incubated with 200 l of 125 I-thrombin:PN1 complexes for varying lengths of time at either 4 or 37°C. After the incubation, the cells were placed on ice, and the binding medium containing complexes was aspirated. The cells were washed four times with ice-cold PBS. Heparin-associated complexes were measured by stripping the cells with 1 ml of HEPESbuffered saline containing 100 g/ml soluble heparin and quantifying the dissociated complexes by ␥ counting. Cell-associated complexes, either before or after dissociation of the heparin-bound complexes, were measured by lysing the cells with 1 ml of 10% SDS and ␥-counting the resulting lysate. The degree to which various concentrations of heparin or GST-RAP inhibited the cell-surface binding of thrombin:PN1 complexes was ascertained by mixing the preformed complexes with various concentrations of heparin or GST-RAP before incubating the complexes with the cells. Nonspecific binding was measured to be Ͻ10% of the specific binding by incubation of duplicate cultures with a 100-fold excess of unlabeled thrombin:PN1 complexes.
RESULTS
Human astrocytes efficiently internalize and degrade thrombin and thrombin:PN1 complexes
In previous studies, we have demonstrated that rat brain astrocytes secrete soluble PN1 and bind, internalize, and degrade thrombin:PN1 complexes (Rosenblatt et al., 1987) . For the mechanistic experiments presented here, we required human astrocytes because all the interacting proteins were of human origin. We therefore chose the astrocytic cell line CCF-STTG1, which most closely resembles normal human astrocytes. Confirming previous reports (Barna et al., 1985) , Ͼ80% of these cells in culture express the astrocyte-specific marker GFAP (data not shown).
To ascertain whether human astrocytes internalize thrombin and thrombin:PN1 complexes, confluent cultures were incubated with 10 ng/ml 125 I-thrombin:PN1 complexes over a several-hour time course (Fig. 1A) . By 6 h, the cells had catabolized a total of 16 fmol of complexes. To demonstrate that the degradation was dependent on the concentration of 125 I-thrombin:PN1 complexes, and to gain an estimate of the levels of PN1 secreted by these human astrocytes, the experiment was repeated over a longer time course in the presence of 100 ng/ml 125 I-thrombin:PN1 complexes or 100 ng/ml free 125 I-thrombin (Fig. 1B) . As expected, the total amount of complexes catabolized was dependent on the concentration of 125 I-thrombin:PN1 complexes added at the beginning of the experiment. The 10-fold increase in the concentration of 125 I-thrombin:PN1 complexes resulted in a fourfold increase in catabolism observed at the 6-h time point. There was also significant catabolism of 125 I-thrombin alone, which has been shown previously to correlate with the presence of PN1 on rat astrocyte cell surfaces (Monard et al., 1983; Rosenblatt et al., 1987) . Indeed, chromogenic assays for thrombin activity in the presence and absence of these human astrocytes indicated that a potent thrombin inhibitor was associated with the cell surface (data not shown). Furthermore, the length of time the cells were serum-starved had no effect on the uptake of free thrombin (data not shown).
TM complexation does not affect the rate at which thrombin or thrombin:PN1 complexes are internalized
To ascertain whether TM was internalizing some or all of the thrombin and thrombin:PN1 complexes, we measured the competition of added soluble TM fragment TMEGF(4-5-6) on the binding and internalization of 125 I-thrombin and 125 I-thrombin:PN1 complexes. This fragment contains the primary, nanomolar affinity binding site for thrombin and, when added in soluble form, would be expected to compete efficiently for thrombin binding to cell-surface TM. A large excess of TMEGF(4-5-6) (20 g/ml) was mixed with 125 I-thrombin either before or after addition of PN1, and complexes were formed at 37°C as usual. Figure 2 shows that the rate at which the cells internalized the 125 I-thrombin:PN1 complexes was not altered by addition of TMEGF(4-5-6) despite the fact that this fragment binds to thrombin with nanomolar affinity (White et al., 1995) . The results were indistinguishable whether the TMEGF(4-5-6) was added to the thrombin before or after PN1. This result is interesting for two reasons. First, it suggests that complexation of thrombin with TMEGF(4-5-6) does not preclude complexation with PN1, a result in line with that obtained with antithrombin III. Second, it suggests that
FIG. 1. Degradation of
125 I-thrombin and 125 I-thrombin:PN1 complexes by human astrocytes. Duplicate confluent human astrocyte cultures were prepared in 24-well plates. The cells were rinsed twice with binding medium before incubation at 37°C in binding medium containing (A) 10 ng/ml 125 I-thrombin: PN1 complexes or (B) 100 ng/ml 125 I-thrombin:PN1 complexes (ⅷ) or the equivalent concentration of 125 I-thrombin alone ( f ). At each time point, 100 l of the incubation medium was assayed for TCA-soluble radioactivity as described in Experimental Procedures.
although TM is indeed present on these astrocyte cell surfaces (data not shown), it does not play a significant role in thrombin internalization.
Human astrocytes internalize thrombin:PN1 complexes by a mechanism involving both heparin and LRP, but the initial cell-surface binding of complexes is primarily heparin-dependent
In previous studies, the binding and internalization of thrombin:PN1 complexes by human fibroblasts were shown to proceed by a two-step mechanism. In the first step, complexes bind to the cell surface via heparins, and in the second step, they are internalized by the LRP (Knauer et al., 1997a,b) . To investigate the mechanism by which the catabolism of 125 I-thrombin:PN1 complexes occurs in human astrocytes, experiments were done on cells incubated at 37 and 4°C to differentiate internalization and degradation from binding. Addition of low concentrations of soluble heparin or a GST-RAP fusion protein was found to inhibit the internalization and degradation of 125 I-thrombin:PN1 complexes by ϳ68% at 37°C (Fig. 3) . The concentration of GST-RAP required to achieve 68% inhibition of internalization and degradation in astrocytes, ϳ30 nM, was comparable to the concentration of GST-RAP required to achieve the same effect in human fibroblasts (Knauer et al., 1997a) . These experiments were repeated using higher concentration ranges of both heparin and GST-RAP, with essentially no further increase in inhibition (data not shown). These data clearly indicate a role for both heparins and the LRP in the catabolism of thrombin:PN1 complexes by human astrocytes, but do not indicate the order in which these components are used.
In parallel studies conducted at 4°C, the effects of soluble GST-RAP and heparin on the binding of 125 Ithrombin:PN1 complexes to the cell surface were measured. In contrast to the effectiveness of both soluble heparin and GST-RAP to potently inhibit 125 I-thrombin: PN1 internalization and catabolism, only soluble heparin was found to be an effective inhibitor of the binding of complexes to the cell surface (Fig. 4) . At a concentration of 30 nM GST-RAP, only a 10% reduction in cellsurface binding was observed, far disproportional to the 68% reduction in complex catabolism observed using the same GST-RAP concentration (Figs. 3B and 4B) . Heparin, in contrast, was as effective in inhibiting complex binding to the cell surface as it was in inhibiting complex catabolism, at proportional concentrations (Figs. 3A and  4A ). These data suggest a temporal sequence of events in human astrocytes similar to that observed with human fibroblasts where the complexes first bind to heparins at the cell surface and are subsequently internalized via the LRP.
The binding of 125 I-thrombin:PN1 complexes to heparins at the cell surface of human astrocytes is an effective concentration mechanism
To evaluate more carefully and quantitatively the ability of cell-surface heparins to bind and concentrate the 125 I-thrombin:PN1 complexes from solution, we measured complex dissociation in the presence or absence of soluble heparin.
125 I-Thrombin:PN1 complexes were in -FIG. 3 . Degradation of 125 I-thrombin:PN1 complexes by human astrocytes is inhibited by soluble heparin and GST-RAP. Human astrocyte cultures were prepared and rinsed as described in Fig.  1 . Triplicate wells were incubated at 37°C in binding medium containing 10 ng/ml 125 I-thrombin:PN1 complexes and increasing concentrations of (A) heparin or (B) GST-RAP. After 6 h, 100 l of culture medium was removed, and the TCA-soluble radioactivity was determined.
FIG. 2.
The rate at which 125 I-thrombin is internalized by human astrocytes is not affected by addition of soluble TMEGF(4-5-6). Human astrocyte cultures were incubated in binding medium containing 10 ng/ml 125 I-thrombin:PN1 complexes at 37°C for varying times and in the presence ( f ) or absence (ⅷ) of soluble TMEGF(4-5-6). At the end of the experiment, the cells were placed on ice, the medium was removed, and the cells were washed four times with PBS. The cell surface-bound complexes were removed by treatment of the cells with HEPES-buffered saline containing 100 g/ml heparin. The remaining cell-associated and internalized complexes were quantified by dissolution of the cells in 10% SDS. The data shown in this graph are for 125 I-thrombin:PN1 complexes formed before the addition of TMEGF(4-5-6), although similar data were obtained from experiments in which TMEGF(4-5-6) was mixed with thrombin and 125 I-PN1 before complexation. cubated with astrocyte cultures at 4°C for 3 h to reach an approximate binding equilibrium. The cultures were then rinsed and placed at 4°C in binding medium alone or medium containing soluble heparin. At the indicated time points (Fig. 5) , the amount of 125 I-thrombin:PN1 complexes dissociated into the medium was measured. In the absence of heparin, the dissociation of the complexes into the medium was barely measurable over the 30-min time course examined. In the presence of added soluble heparin, however, dissociation was extremely rapid. Nearly all of the bound complexes dissociated by 10 min, and half-maximal dissociation was seen as early as 5 min. These data support the role of heparin in the initial cell-surface binding of the complexes observed in Fig. 3 and demonstrate the efficiency of this process. In principle, once a thrombin:PN1 complex is bound to cellsurface heparins, binding avidity would make this nearly an irreversible process.
The efficient internalization and degradation of 125 I-thrombin:PN1 complexes requires a functional heparin binding site in PN1
To demonstrate the significance of cell-surface heparin binding in the catabolism of 125 I-thrombin:PN1 complexes, we used a site-directed mutant of PN1 that is deficient in heparin binding. This mutant, designated PN1(K7E), has been shown previously to form complexes with thrombin that differ functionally from complexes of thrombin with the native form of PN1 only in their ability to bind heparin (Stone et al., 1994) . The use of this mutant is key in the present studies, because the ability of soluble heparin to compete for complex binding and inhibit complex catabolism could also be explained by the competition of the complexes and soluble heparin for binding to a rate-limiting component on the cell surface at a common site. To test the role of the heparin binding site in PN1 directly, the degradation rates of 125 I-thrombin:PN1 complexes and 125 I-thrombin: PN1(K7E) complexes were evaluated in parallel in cultures of human astrocytes over a 6-h time course (Fig. 6) . As expected from our previous data, the degradation rate of 125 I-thrombin:PN1 complexes was very high, reaching ϳ30 fmol by 12 h. In contrast, the degradation rate of 125 I-thrombin:PN1(K7E) complexes was sharply low-
FIG. 4. Binding of 125
I-thrombin:PN1 complexes to human astrocytes is inhibited by soluble heparin, but is not inhibited significantly by GST-RAP. Duplicate confluent human astrocyte cultures in 24-well plates were placed at 4°C, and the cells were rinsed twice with binding medium. Triplicate wells were then incubated in bicarbonate-free binding medium containing 100 ng/ml 125 I-thrombin:PN1 complexes, and increasing concentrations of (A) heparin or (B) GST-RAP added concurrently. After 3 h, the cells were washed rapidly four times with PBS, and the cell-associated complexes were quantified by dissolution of the cells in 10% SDS. Nonspecific binding was determined to be Ͻ10% by addition of a 100-fold excess of unlabeled complexes.
FIG. 5. Soluble heparin promotes the rapid dissociation of
125 Ithrombin:PN1 complexes form the cell surface of human astrocytes. Confluent human astrocyte cultures were prepared in 24-well plates, placed at 4°C, rinsed, and then incubated with 100 ng/ml 125 I-thrombin:PN1 complexes as in Fig. 3 . After a 3-h incubation, the culture medium was removed, and new binding medium was added (ⅷ) or new binding medium containing 1 mg/ml soluble heparin ( f ) was added. At the indicated times after the addition of the fresh media, the radioactivity that had dissociated into the media was quantified by ␥ counting.
FIG. 6. The degradation of
125 I-thrombin:PN1(K7E) complexes is much less efficient than the degradation of native 125 I-thrombin:PN1 complexes. Confluent human astrocyte cultures were prepared as in Fig. 1 and then incubated in binding medium containing 10 ng/ml 125 I-thrombin:PN1 complexes (ⅷ) or 10 ng/ml 125 I-thrombin:PN1(K7E) complexes ( f ). At the indicated time points, 100 l of the media was removed and the TCAsoluble radioactivity was determined. The amount of complexes presented to the cells was quantified by SDS-gel electrophoresis and phosphorimaging as previously described (Howard and Knauer, 1986) . ered, with ϳ4 fmol degraded during the same time period. This eightfold difference in degradation rate demonstrates the significant role of the initial cell-surface heparin binding in the efficient catabolism of 125 Ithrombin:PN1 complexes.
Our hypothesis was that the clearance of thrombin requires at least five steps: first, thrombin must form a complex with PN1; second, the complexes bind to cellsurface heparins; third, they are handed off to the LRP; fourth, they are internalized; and finally, they are degraded. The experiment shown in Fig. 6 demonstrated that degradation of thrombin:PN1(K7E) complexes was severely impaired; however, the step at which these complexes were hindered was not demonstrated. As our hypothesis is that the heparin binding site in PN1 serves to localize the thrombin:PN1 complexes to the cell surface and poise them for LRP-mediated endocytosis, we measured the amount of complexes that were bound to cell-surface heparins and the amount of complexes that were internalized. The 125 I-thrombin:PN1 and 125 Ithrombin:PN1(K7E) complexes that were bound to cellsurface heparins were measured by stripping the cells of heparin-bound complexes by addition of soluble heparin (see Experimental Procedures for details of cell-surface stripping). Although several femtomoles of wild-type complexes were stripped from the cultures, no 125 Ithrombin:PN1(K7E) complexes were found associated to cell-surface heparins. After stripping, the remaining complexes associated with the cell (either bound to LRP or internalized) were measured. Whereas the internalization of 125 I-thrombin:PN1 complexes increased in a relatively linear fashion over the 45-min period examined, the internalization of 125 I-thrombin:PN1(K7E) complexes was negligible (Fig. 7) . This correlates directly with the decreased degradation rate of 125 I-thrombin: PN1(K7E) complexes seen in Fig. 6 , and the simplest interpretation of these data is that the rate of internalization is proportional to the concentration of complexes available bound to cell-surface heparins ready for LRP internalization. As the cell-surface concentration of 125 Ithrombin:PN1(K7E) complexes is significantly lower than the cell-surface concentration of 125 I-thrombin:PN1 complexes, the complex internalization rate is similarly lowered.
DISCUSSION
The rapid removal of protease:SERPIN complexes from the extracellular space is crucial, because an imbalance in the activity of proteases may contribute, even if secondarily, to the neurodegenerative process (Cunningham, 1992; Cunningham et al., 1993) . Balance between thrombin and PN1 appears to be important in apoptosis and is clearly disrupted due to an increased concentration of thrombin in the brains of AD patients. We therefore sought to determine the biochemical mechanism of thrombin and thrombin:PN1 complex clearance in human astrocytes. We first showed that TM, a likely candidate, does not seem to be playing a significant role in thrombin clearance by astrocytes. This result leaves open the question of the role that TM is playing in the brain. The other candidate protein, LRP, was indeed found to mediate catabolism of thrombin:PN1 complexes in human astrocytes, as it had been shown to do in fibroblasts (Knauer et al., 1997a) . Our experiments demonstrate that catabolism of thrombin depends on prior complexation with PN1. Second, we demonstrate that in the presence of RAP, a generalized antagonist of LRP, the catabolism of thrombin:PN1 complexes is largely inhibited. Thus, the LRP mechanism is the primary mechanism for thrombin catabolism in human astrocytes.
It was important to demonstrate the path followed by the thrombin:PN1 complexes being internalized by human astrocyte cells, because LRP has been shown to follow several different mechanisms for protease: SERPIN complex internalization. For example, internalization of urokinase-type plasminogen activator (uPA) requires two receptors, uPA receptor and LRP. Subsequent internalization and degradation of the bound plasminogen activator inhibitor type-1:uPA complexes require LRP and are inhibited by RAP (Herz et al., 1991; Conese et al., 1994) . The receptor that mediates catabolism of thrombin:PN1 complexes in human fibroblast cells is also LRP Knauer, 1986, 1987) .
FIG. 7. The rapid internalization of
125 I-thrombin:PN1 complexes is dependent on a functional heparin binding site in the PN1 moiety. Human astrocyte cultures were incubated in binding medium containing 10 ng/ml 125 I-thrombin:PN1 complexes (ⅷ) or 125 I-thrombin:PN1(K7E) complexes ( f ). After the indicated times, the cultures were placed on ice, the binding medium was removed, and the cells were washed four times with PBS. Cell-surface heparin-bound complexes were stripped by treatment of the cells with HEPES-buffered saline containing 100 g/ml heparin (Knauer et al., 1997a) . The cells were then lysed with 10% SDS, and ␥ counting was used to measure internalized complexes. A: Internalized complexes. B: Dissociated complexes.
However, the uPA receptor plays no role in the binding and internalization of thrombin:PN1 complexes in fibroblasts. Instead, cell-surface heparins mediate the initial binding of thrombin:PN1 complexes to fibroblast cell surfaces (Stone et al., 1994; Knauer et al., 1997a) . Neither PN1 alone nor thrombin alone is internalized at a significant rate, and internalization of thrombin clearly requires the interaction of a specific region of PN1 with cell-surface heparins and the interaction of a distinct region of PN1 with LRP (Stone et al., 1994; Knauer et al., 1997b) . Thus, for human fibroblasts, thrombin:PN1 complexes are internalized by a two-step mechanism requiring a preassociation of the complexes to cell-surface heparins and subsequent internalization by LRP binding to a portion of PN1.
The experiments presented here demonstrate that LRP provides the primary clearance mechanism for thrombin in human astrocytes. Furthermore, the two-step heparin binding and LRP internalization mechanism that was shown for fibroblasts (Knauer et al., 1997a,b) appears to be occurring in astrocytes as well. Heparin was shown to inhibit both binding and internalization of thrombin:PN1 complexes, and complexes of thrombin with a variant form of PN1 that is deficient in heparin binding, PN1(K7E), were neither bound nor internalized. In contrast, GST-RAP significantly inhibited only internalization, but not the cell-surface binding, of thrombin:PN1 complexes. These data provide convincing evidence for the same two-step mechanism that required cell-surface heparins as the initial binding component as was observed for human fibroblasts.
The role of cell-surface heparin appears to be pivotal in the catabolic process. First, the LRP-mediated internalization rate of thrombin:PN1 complexes by astrocytes observed in the present studies is extremely rapid and remarkably similar to that of fibroblasts (Knauer et al., 1997a,b) . A closer look at the kinetics of the different steps in the process reveals that the initial binding to cell-surface heparins is the rate-limiting step in the internalization and subsequent degradation of the complexes. The amount of cell-associated complexes after 30 min of incubation with 10 ng/ml complexes was 2.5 fmol, whereas the amount of complexes degraded after 2 h was 12 fmol, so all the cell-associated complexes were efficiently degraded. Also, once bound to cellsurface heparins, the thrombin:PN1 complexes do not dissociate unless soluble heparin is added (Fig. 5) . This is apparently due to avidity, because of the large number of heparin binding sites available at the cell surface. The end result is that once a complex becomes heparinassociated at the cell surface, it is essentially destined for subsequent LRP-mediated internalization. Glycoform variation has been observed between fibroblasts and brain tissue (Parekh et al., 1987) , and therefore establishment of the mechanism of thrombin:PN1 complex internalization in astrocytes could not be inferred from results of experiments in fibroblasts. The fact that astrocytes, which are very different from fibroblasts, appear to catabolize thrombin:PN1 complexes efficiently by the same two-step mechanism strongly suggests that this mechanism might be general.
The demonstration that thrombin:PN1 complexes are catabolized by astrocytes predominantly by an LRPdependent mechanism is significant, because it provides a biochemical mechanism for the accumulation of thrombin:PN1 complexes in the brains of AD patients. Recently, several groups have shown a genetic association between LRP polymorphisms and AD (Kang et al., 1997; Lendon et al., 1997; Wavrant-DeVrieze et al., 1997; Kamboh et al., 1998) , although this association is still controversial (Clatworthy et al., 1997; Fallin et al., 1997) . When senile plaques were analyzed by immunostaining, several ligands of LRP were found in the plaques (Rebeck et al., 1995) . LRP itself was also present in the senile plaques, and hypertrophic reactive astrocytes that were found associated with the plaque core in AD brains stained strongly for the ␣-subunit of LRP . A buildup of thrombin:PN1 complexes is also found in AD brains (Akiyama et al., 1992) .
The accumulation of thrombin:PN1 complexes in the brains of AD patients may be due to malfunctioning of LRP, the only efficient catabolic system for clearance of these complexes. Rebeck et al. (1995) propose an attractive model in which LRP, which has multiple binding sites for its different ligands, binds to apolipoprotein E:amyloid ␤-protein complexes in the senile plaque and subsequently would recruit various other LRP ligands to the plaque. Our studies provide convincing evidence that LRP is the primary vehicle for clearance of thrombin in astrocytes, and provide details of the complex mechanism of clearance. The results provide a possible mechanistic link between synapse loss from accumulation of thrombin and genetic polymorphisms in LRP that have been linked recently to AD.
